Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 4 for:    hVIVO | Recruiting, Active, not recruiting, Enrolling by invitation Studies | United Kingdom
Previous Study | Return to List | Next Study

COVID-19 SARS-CoV-2 Screening Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04740320
Recruitment Status : Recruiting
First Posted : February 5, 2021
Last Update Posted : February 11, 2021
Sponsor:
Collaborator:
Hvivo
Information provided by (Responsible Party):
Imperial College London

Brief Summary:
The aim of this screening protocol is to assess volunteers for their potential eligibility to participate in a dose finding human experimental infection study in healthy subjects using a GMP-produced SARS-CoV-2 wild type strain

Condition or disease
Covid19

Detailed Description:

Recruitment will be done through a number of channels:

  • Approved advertising, including social medial
  • hVIVO volunteer database
  • Referral
  • Organic search, i.e. where the volunteer has learned of this study by doing a Google search or through friends or family rather than due to any advertising Following Research Ethics Committee approval of the full study, screened subjects who confirm their willingness to participate in the SARS-CoV-2 human infection challenge characterization study will be invited to consider the study-specific PIS-ICF and enter the final study consenting process.

The number of subjects who are to be recruited will depend on specific sample-size requirements for the SARS-CoV-2 human infection characterization study.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 250 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 90 Days
Official Title: Screening Protocol for a Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain
Actual Study Start Date : December 15, 2020
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021

Group/Cohort
Healthy Volunteers
Volunteers asked to register details on a SARS-CoV-2 specific web page UKcovidchallenge.com. They will be contacted with a short webform questionnaire to be performed prior to a follow-up telephone questionnaire or will be asked to complete a telephone questionnaire. If inclusion/exclusion criteria are met, appointment for a screening visit will be scheduled. Screening appointments will be conducted at hVIVO. Written consent for screening will be obtained prior to any history-taking, examination or tests are carried out. Medical history will be requested from GP to assess suitability. Once the SARS-CoV-2 characterization study is approved, potential participants will be given the study specific PIS detailing the full study and experimental procedures. The opportunity to discuss further and ask questions will be available prior to booking a study visit.



Primary Outcome Measures :
  1. Participants enrolled [ Time Frame: 6 months ]
    Number of participants enrolled in main study


Biospecimen Retention:   Samples Without DNA
Samples of tissue, cells and fluids will be stored according to Imperial College London and hVIVO SOPs as appropriate. Samples will be pseudoanonymised with participant identification numbers only and the anonymisation key kept in a separate locked location accessible only to the hVIVO clinical study team. Samples may be used for further assays or in other ethically approved studies. Samples and data may be shared with UK and international collaborators in studies that have been approved by local ethics committees and subject to a valid Materials Transfer Agreement. At the end of the study any remaining samples will be either destroyed, transferred to the sponsor or subject to consent, transfer to and maintained under hVIVOs HTA licenses.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy Volunteers aged 18-30
Criteria

Inclusion Criteria:

  1. An informed consent document signed and dated by the participant and the Investigator.
  2. Male or female, age between 18 and 30 years inclusive (at the time of the study consent)
  3. Seronegative to the challenge virus SARS-CoV-2
  4. Women of childbearing potential with a documented menstrual period within 28 days before the first dose (unless using a contraceptive method that suppressed menstruation as indicated in the study protocol) and willing and able to use contraception as described in the study protocol from 4 weeks before the scheduled date of viral challenge until 30 days after receipt of the final dose of study medication. Negative urine pregnancy test will be required at screening plus, on admission to the quarantine unit, a Negative serum beta human chorionic gonadotropin (β-hCG) is a required. Also a negative urinary pregnancy test prior to virus challenge is also required.
  5. Men who are willing to use one of the contraception methods described in the study protocol, from the time of the date of viral challenge, until 90 days after receipt of the final dose of study medication.
  6. In good health with no history of clinically significant medical conditions (as described in Exclusion criteria) that would interfere with subject safety, as defined by medical history, physical examination and routine laboratory tests, ECG, and Chest X-Ray* and determined by the Investigator at a screening evaluation and/or at admission to the Quarantine Unit.
  7. Subjects will have a documented medical history either prior to entering the study and/or following medical history review with the study physician at screening
  8. Using the QCOVID tool, an absolute risk of COVID-associated death of 1 in 250,000 (0.0004%) or less and COVID-associated hospital admission of 1 in 5000 (0.02%) or less), or alternative risk threshold at the discretion of the CI with advice from the DSMB

    Exclusion Criteria:

    Any potential subject who meet any of the criteria below will be excluded from participating in this study.

    Clinical history 1. History or evidence of any clinically significant or currently active cardiovascular, (including thromboembolic events), respiratory, dermatological, gastrointestinal, endocrine, haematological, hepatic, immunological, rheumatological, metabolic, urological, renal, neurological, psychiatric illness. Specifically:

    a) Subjects with any history of physician diagnosed and/or objective test confirmed asthma, chronic obstructive pulmonary disease, pulmonary hypertension, reactive airway disease, or chronic lung condition of any aetiology or who have experienced:

    o Significant/severe wheeze in the past

    • Respiratory symptoms including wheeze which has ever resulted in hospitalisation
    • Known bronchial hyperreactivity to viruses b) History of thromboembolic, cardiovascular or cerebrovascular disease c) History or evidence of diabetes mellitus d) Any concurrent serious illness including history of malignancy that could interfere with the aims of the study or a subject completing the study. Basal cell carcinoma within 5 years of treatment or with evidence of recurrence is also an exclusion e) Migraine with associated neurological symptoms such as hemiplegia or vision loss. Cluster headache/migraine or prophylactic treatment for migraine f) History or evidence of autoimmune disease or known immunodeficiency of any cause.

      g) Other major disease that, in the opinion of the Investigator, could interfere with a subject completing the study and necessary investigations.

      h) Immunosuppression of any type. 2. Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx, a clinically significant history of epistaxis (large nosebleeds) within the last 3 months, nasal or sinus surgery within 6 months of inoculation.

      3. Clinically active rhinitis (including hay fever) or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and/or requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of admission to quarantine.

      4. History of anaphylaxis and/or a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the PI.

      5. History or presence of alcohol addiction, or excessive use of alcohol (average weekly intake in excess of 28 units alcohol; one unit being a half glass of beer, a small glass of wine or a measure of spirits).

      6. Psychiatric illness including subjects with a history of depression and/or anxiety with associated severe psychiatric comorbidities, for example psychosis. Specifically,

      a) Subjects with history of anxiety-related symptoms of any severity within the last 2 years if the Generalized Anxiety Disorder-7 score is ≥4 b) Subjects with a history of depression of any severity within the last 2 years if the Patient Health Questionnaire-9 score is ≥4

      7. Current smokers or subjects who have smoked ≥5 pack years at any time [5 pack years is equivalent to one pack of 20 cigarettes a day for 5 years].

      • Subjects who have smoked <5 pack years - at any time in the 3 months prior to admission to the quarantine unit they have used tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch) or electronic cigarettes.

      8. Family history of 1st degree relative aged 50 years or less with sudden cardiac or unexplained death 9. Family History of Severe COVID or response to any other viral disease e.g. Guillain-Barré Measurements and investigations

      1. A total body weight of ≤ 50g and a Body Mass Index (BMI) ≤18 kg/m2 and ≥28 kg/m2. The upper limit of BMI may be increased to ≤ 30kg/m2 at the PI's discretion, in the case of physically fit muscular individual
      2. Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
      3. Any clinically significant abnormal finding on screening biochemistry, haematology and microbiology blood tests or urinalysis i.e. grade 1 lab abnormalities (or above, see Appendix 4 Toxicity Grading Scale for Laboratory AEs) apart from minor deviations which are clinically acceptable and approved by the Principal Investigator

        a) Elevated random glucose and HbA1C b) Positive HIV, active/chronic hepatitis A, B or C test. c) Confirmed positive test for drugs of abuse on admission and urinary cotinine at quarantine.

      4. A forced expiratory volume in 1 second (FEV1) and a forced vital capacity (FVC) <80% of predicted value calculated using ATS/ERS guidance
      5. Twelve-lead ECG recording with clinically relevant abnormalities as judged by the study physician/PI.

        Recent respiratory infection

      6. History of, or currently active symptoms suggestive of upper or lower respiratory tract infection (including reduced sense of taste and smell, raised body temperature and/or persistent cough) within 6 weeks prior to viral challenge.
      7. Presence of cold-like symptoms and/or fever (defined as subject presenting with a temperature reading of >37.9ºC) Receipt of medications and interventions
      8. Evidence of a live vaccine within 60 days prior to the planned date of viral challenge, a non-live vaccine within 30 days prior to the planned date of viral challenge, or intention to receive any vaccination(s) before the day 28 follow-up visit. (NB. No travel restrictions applied after the Day 28 Follow-up visit).
      9. Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of viral challenge or planned during the 3 months after the final visit.
      10. Medications

        a) Use of any medication or product (prescription or over-the-counter), for symptoms of hayfever, nasal congestion or respiratory tract infections or dermatitis/eczema including the use of regular nasal or medium-high potency dermal corticosteroids, antibiotics and First Defence™ (or generic equivalents) within 7 days prior to the planned date of viral challenge apart from those described and allowed in Permitted Medication or agreed by the Principle Investigator b) Receipt of any investigational drug within 3 months prior to the planned date of viral challenge.

        c) Receipt of three or more investigational drugs within the previous 12 months prior to the planned date of viral challenge.

        d) Prior inoculation with a virus from the same virus-family as the challenge virus.

        e) Receipt of systemic (intravenous and/or oral) glucocorticoids or systemic antiviral drugs within 6 months prior to the planned date of viral challenge.

        f) Over the counter medications (e.g., paracetamol or ibuprofen) where the dose taken over the preceding 7 days prior to the planned date of viral challenge had exceeded the maximum permissible 24-hour dose (e.g., >4g per day of paracetamol over the preceding week).

        g) Use or anticipated use within 7 days prior to the planned date of viral challenge and during the conduct of the study of concomitant medications (prescription and/or non-prescription), including vitamins or herbal and dietary supplements within the specified windows.

        h) Chronically used medications, vitamins or dietary supplements, including any medication known to be a moderate/potent inducer or inhibitor of cytochrome P450 enzymes, within 21 days prior to the planned date of viral challenge.

        i) Subjects who have received any systemic chemotherapy agent, immunoglobulins, or other cytotoxic or immunosuppressive drugs at any time.

      11. Prior participation in another human viral challenge study in the preceding 12 months taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study.
      12. Any nasal sampling procedure in the 6 months before date of expected viral challenge in this study. Nasal swabs are allowed.

        General

      13. Subject was mentally or legally incapacitated in the opinion of the Investigator.
      14. Females who:

        1. Are breastfeeding within 6 months of study commencement, or
        2. Had been pregnant within 6 months prior to the study, or
        3. Had a positive pregnancy test at any point during screening or prior to inoculation with challenge virus
      15. Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 3 years, the elderly (>65 years), immunosuppressed persons, or those with chronic respiratory disease Other
      16. Was employed or was a first-degree relative of anyone employed by the Sponsor, a participating clinical trial site, or any Contract Research Organisation involved in the study.
      17. Any other reason that the Investigator considered made the subject unsuitable to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04740320


Contacts
Layout table for location contacts
Contact: Chris Chiu +442083832301 c.chiu@imperial.ac.uk

Locations
Layout table for location information
United Kingdom
hVIVO Services Ltd, QMB Bioenterprise building Recruiting
London, United Kingdom, E1 2AX
Contact: Mariya Kalinova    0207 756 1414    m.kalinova@hvivo.com   
Sponsors and Collaborators
Imperial College London
Hvivo
Investigators
Layout table for investigator information
Principal Investigator: Chris Chiu Imperial College London
Layout table for additonal information
Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT04740320    
Other Study ID Numbers: 20IC6378
First Posted: February 5, 2021    Key Record Dates
Last Update Posted: February 11, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Imperial College London:
COVID19
Coronavirus
Coronavirus disease 19
SARS-COV-2
Healthy volunteer
human challenge